Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform
- 25 November 2021
- journal article
- editorial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (22), 2017-2019
- https://doi.org/10.1056/nejmp2113679
Abstract
Aducanumab’s price can inform the drug-pricing policy debate because it responds to key features of the market environment for physician-administered drugs: Medicare’s reimbursement formula, payment to physicians for infused drugs, and cost-sharing requirements.Keywords
This publication has 3 references indexed in Scilit:
- Price Differences To Insurers For Infused Cancer Drugs In Hospital Outpatient Departments And Physician OfficesHealth Affairs, 2021
- Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?JAMA, 2021
- Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug CoverageHealth Affairs, 2019